期刊文献+

小剂量VCR联合Endostar抑制PLA-802细胞系VEGF表达 被引量:3

The effect of the combination of small dosage of VCR and Endostar on the expression of VEGF in PLA-802 cell line
下载PDF
导出
摘要 目的探讨小剂量长春新碱(VCR)联合恩度(Endostar,Endo)对横纹肌肉瘤细胞生长的影响及其机制。方法体外培养PLA-802细胞系,用小剂量Endo、VCR单独或联合处理细胞。用MTT和流式细胞仪检测细胞的生长和细胞周期;用RT-PCR和Western blot检测药物处理后细胞内VEGFmRNA和蛋白水平;用ELISA检测上清液中VEGF水平。结果单独应用VCR(0.5和2.0μg/mL)和单独应用Endo(2.0μg/mL)均能够抑制PLA-802细胞的增殖,并促进细胞的凋亡,抑制细胞内VEGF的表达和生成。而两者联合应用时,上述作用得到明显增强。结论小剂量VCR与Endo联合应用协同抑制PLA-802细胞中VEGF的生成和表达,诱导细胞凋亡。 Objective To explore the effect of the combination of small dosage of VCR and Endostar(Endo) on rhabdomyosarcoma cells and its mechanisms.Methods PLA-802 was cultured and treated with small dosage of VCR,Endostar singly or both.MTT was used to examine the cells proliferation,and flow cytometry was used for the checking cell cycle.While,RT-PCR and Western blot were for the expression of VEGF mRNA and protein levels.ELISA was for the generation of VEGF in supernatant.Results VCR(0.5 and 2.0 μg/mL) or Endo(2.0 μg/mL) used separcitely inhibited the cell proliferation and promoted the apoptosis,and also inhibited the expression and generation of VEGF.When the cells were treated with VCR and Endo together,the inhibitory effect of them were significantly strengthened.Conclusion The combination of VCR and Endostar synergistically inhibit the expression and generation of VEGF and induces the apoptosis in PLA-802 cells.
出处 《基础医学与临床》 CSCD 北大核心 2011年第1期32-36,共5页 Basic and Clinical Medicine
基金 重庆市卫生局科研项目(2008-2-381)
关键词 ENDOSTAR 长春新碱 PLA-802细胞 血管内皮生长因子 Endostar VCR PLA-802 cell VEGF
  • 相关文献

参考文献12

  • 1Hashimoto K, Man S, Xu P, et al. Potent preclinical impact pf metronomic low-dose oral topotecan combined with the antiangtiogenic drug pazopanib for the treatment of ovarian cancer [J]. Mol Cancer Ther, 2010, 9:996-1006.
  • 2Tang TC, Man S, Lee CR, et al. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma [ J ]. Neoplasia, 2010, 12 : 264 - 274.
  • 3Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: implication for cancer therapy [ J ]. Expert Opin Biol Ther, 2009, 9:1347 -1356.
  • 4Cuevas I, Boudreau N. Managing tumor angiogenesis: lessons from VEGF-resistant tumors and wounds [ J ]. Adv Cancer Res, 2009, 103:25-42.
  • 5王霜,刘晓力,原少斐,杜红延.抗人stathmin 1单克隆抗体联合长春新碱抑制K562细胞生长[J].基础医学与临床,2010,30(2):179-184. 被引量:2
  • 6徐玲,叶京明,赵建新,段学宁,刘荫华.长春瑞滨联合顺铂对蒽环类联合紫杉类辅助化疗失败的乳腺癌患者的疗效分析[J].中华医学杂志,2009,89(10):683-685. 被引量:7
  • 7Mewhort-Buist TA, Liaw PC, Patel S, et al Treatment of endothelium with the chemotherapy agent vincrestine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma [ J ]. Thromb Res, 2008,122:418 -426.
  • 8Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma [ J ]. J Cancer Res Clin Oncol, 2010, 136:1201-1211.
  • 9康欣梅,张清媛,佟丹丹,赵文辉.低剂量环磷酰胺联合人参皂甙Rg3抑制小鼠肺癌肿瘤血管生成的实验研究[J].中国中西医结合杂志,2005,25(8):730-733. 被引量:14
  • 10Rad FH, Le Buanec H, Paturance S, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases [ J ]. Proc Natl Acad Sci USA, 2007, 104 : 2837 - 2842.

二级参考文献40

  • 1井晓荣,刘丽,赵辉,张惠中.Stathmin基因表达与肿瘤化疗药物敏感性的关系[J].第四军医大学学报,2005,26(9):784-788. 被引量:8
  • 2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, National Cancer Institute of Canada. J Natl Cancer Inst, 2000,92:205-216.
  • 3Sakamoto G, Inaji H, Akiyama F, et al. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer, 2005,12 Suppl:S1-27.
  • 4Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998,16:2672-2685.
  • 5Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 2002,20 : 1456-1466.
  • 6Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B- 27. J Clin Oncol, 2003,21:4165-4174.
  • 7Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res ,2003,1:309-326.
  • 8Cvitkovic E, Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs, 1992,44 Suppl4:36-45.
  • 9Kamby C ND. Routine management of disseminated disease with special emphasis on bone-directed therapies//Bonadonna G, Hortobagyi G, Gianni AM, eds. Textbook of breast cancer, 2nd ed. London: Martin Dunitz, 2001:161-181.
  • 10Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer, 2001,92 : 2267- 2272.

共引文献18

同被引文献16

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部